接受结肠镜检查的高危人群中自然杀伤细胞活性与结直肠癌的关联
在加拿大蒙特利尔一家大学医院,872例40岁以上高危受试者在结肠镜检查当日采血,用全血自然杀伤(NK)细胞活性检测(IFNG ELISA)评估其与结直肠癌(CRC)的关联。CRC组23例NK细胞活性中位数86.0 pg IFNG/mL,低于无CRC组849例的298.1 pg IFNG/mL(P = .0002);以181 pg/mL为界,敏感性87.0%、特异性60.8%、阴性预测值99.4%。
要点
- CRC组NK细胞活性中位数86.0 pg IFNG/mL,低于无CRC组的298.1 pg IFNG/mL(P = .0002)。
- 以181 pg/mL为切点,检测CRC的敏感性87.0%、特异性60.8%、阴性预测值99.4%。
- 低NK细胞活性者检出CRC的比值比为10.3(95%CI,3.03-34.9)。
核心结论
- 以结肠镜为参考标准,全血NK细胞活性检测识别CRC的敏感性为87.0%,阴性预测值为99.4%。
- 低NK细胞活性者较高NK细胞活性者CRC风险约为10倍(比值比10.3,95%CI 3.03-34.9)。
- 作者认为该检测可能用于临床实践中评估患者的CRC风险。
研究设计与样本
- 开放标签、前瞻性、横断面研究,纳入872例40岁以上高危受试者。
- 受试者于2014年10月至2016年1月在加拿大蒙特利尔一家大学医院接受结肠镜CRC筛查。
- 结肠镜检查当日、操作前采集血样,全血经细胞因子刺激后以ELISA定量NK细胞分泌的干扰素γ(IFNG)。
- 结肠镜下取病灶组织行组织学分析,受试者分为无疾病证据、小于10 mm腺瘤性息肉、10 mm及以上腺瘤性息肉或CRC。
- 采用非参数Mann-Whitney检验比较无CRC与CRC受试者间NK细胞活性,并以受试者工作特征曲线分析评估检测识别CRC的能力。
主要发现
- 经病理分析确诊CRC的23例NK细胞活性中位数为86.0 pg IFNG/mL(四分位距43.3-151.0 pg IFNG/mL)。
- 无CRC的849例NK细胞活性中位数为298.1 pg IFNG/mL(四分位距100.4-920.2 pg IFNG/mL)。
- CRC组与无CRC组NK细胞活性差异有统计学意义(P = .0002)。
- 最准确识别CRC的切点值为181 pg/mL。
- 以该切点检测CRC的敏感性87.0%、特异性60.8%、阳性预测值5.7%、阴性预测值99.4%。
关键数值与推荐
- NK细胞活性检测识别CRC的切点值为181 pg/mL。
- 该切点下敏感性87.0%、特异性60.8%、阳性预测值5.7%、阴性预测值99.4%。
- 低NK细胞活性者检出CRC的比值比10.3(95%CI,3.03-34.9)。
临床怎么用
- 作者认为该NK细胞活性检测可能用于临床实践中评估患者的CRC风险。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Low activity of natural killer (NK) cells has been associated with increased risk of cancer and has been reported in patients with colorectal cancer (CRC). Activity of NK cells can be measured in a small volume of whole blood by a commercially available test. We investigated whether this test could be used to identify patients with CRC, using findings from colonoscopy as a reference standard. METHODS: We performed an open-label, prospective, cross-sectional study of 872 high-risk subjects (more than 40 years old) screened for CRC by colonoscopy at a university hospital in Montreal, Canada from October 2014 through January 2016. Blood samples were collected on the day of colonoscopy, prior to the procedure. The test involves stimulation of whole blood with cytokine that induces NK cells to secrete interferon gamma (IFNG), which is quantified by an ELISA. Tissue samples were taken from lesions during the colonoscopy and analyzed histologically; subjects were classified as having no evidence of disease, adenomatous polyps of less than 10 mm, of 10 mm or more, or CRC. We used the non-parametric Mann-Whitney test to compare NK cell activity between subjects with no evidence of CRC and subjects found to have CRC. Receiver operating characteristic curve analysis was used to assess the ability of the test to identify individuals with CRC. The primary objective was to determine the difference in NK cell activity between subjects with vs without CRC. The secondary objective was the test performance, based on receiver operating characteristic analysis, and cut-off value that most accurately identified individuals with CRC. RESULTS: We found a significant difference in NK cell activity between the 23 subjects with CRC (based on pathology analysis) and the 849 subjects without CRC: subjects found to have CRC by colonoscopy had a median level of 86.0 pg IFNG/mL (inter-quartile range, 43.3-151.0 pg IFNG/mL), whereas subjects without CRC had a median level of 298.1 pg IFNG/mL (inter-quartile range, 100.4-920.2 pg IFNG/mL) (P = .0002). The cut-off value that most accurately identified subjects with CRC was 181 pg/mL. The NK cell activity test identified subjects with CRC with 87.0% sensitivity, 60.8% specificity, a positive predictive value of 5.7%, and a negative predictive value of 99.4%. The odds ratio for detection of CRC in subjects with low NK cell activity vs subjects with higher NK cell activity was 10.3 (95% CI, 3.03-34.9). CONCLUSIONS: Using colonoscopy as the reference standard, a test for NK cell activity in whole blood samples identified patients with CRC with 87.0% sensitivity and a negative predictive value of 99.4%. Subjects with low NK cell activity had a 10-fold higher risk of CRC compared with subjects with high NK cell activity. This test might be used in clinical practice to assess patients for risk of CRC. Clinicaltrials.gov number: NCT02291198.
引用
- Jobin G, Rodriguez-Suarez R, Betito K, et al. Association Between Natural Killer Cell Activity and Colorectal Cancer in High-Risk Subjects Undergoing Colonoscopy. Gastroenterology. 2017. PMID: 28625834. doi:10.1053/j.gastro.2017.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。